---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-007065"
form_type: "8-K"
ticker: "QURE"
cik: "0001590560"
company_name: "uniQure N.V."
filed_at: "2025-05-09T23:59:59+00:00"
generated_at: "2026-05-22T01:41:30.812417+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# uniQure Q1 net loss per share $0.82; AMT-130 granted FDA Breakthrough Therapy designation

## Summary
- Net loss $43.6M ($0.82 per share) vs $65.6M ($1.36) in Q1 2024; revenue down to $1.6M from $8.5M.
- Cash and investments $409M as of Mar 31, 2025; expects funding into H2 2027.
- AMT-130 for Huntington's disease granted FDA Breakthrough Therapy designation in Apr 2025.
- BLA submission guidance for AMT-130 expected in Q2 2025 after official meeting minutes.
- Initial AMT-260 epilepsy data to be presented May 29, 2025; AMT-191 Fabry data in H2 2025.

## SEC filing metadata
- accession: 0001558370-25-007065
- form_type: 8-K
- ticker: QURE
- cik: 0001590560
- company_name: uniQure N.V.
- filed_at: 2025-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590560/000155837025007065/0001558370-25-007065-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590560/000155837025007065/qure-20250509x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-007065
- JSON: https://secwatch.observer/filing/0001558370-25-007065.json
- Plain text: https://secwatch.observer/filing/0001558370-25-007065.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.